It is generally believed that atherosclerosis is a chronic inflammatory disease that is promoted by lifestyle-related diseases, such as hypertension, dyslipidemia, and diabetes. The renin-angiotensin system (RAS) has been demonstrated to play a critical role in the initiation and progression of atherosclerosis, thereby contributing to development of cardiovascular diseases. Angiotensin II (Ang II), a major substrate in RAS, stimulates atherosclerosis through various deleterious effects such as endothelial dysfunction, cellular proliferation and inflammation. Reactive oxygen species (ROS) play a major role in the athero-promoting actions of Ang II. In fact, recent basic and clinical studies demonstrated that pharmacological inhibition of renin-angiotensin system is effective in prevention of atherosclerotic diseases. Elucidation of molecular mechanism of chronic inflammation should lead to development of effective strategies against lifestyle-related diseases.
Renin-angiotensin system
The renin-angiotensin system (RAS) has been considered as a circulating hormonal system that regulates blood pressure, blood flow, fluid volume and electrolyte balance 1) . Angiotensinogen produced in the liver is cleaved to angiotensin (Ang) I in circulation by renin that is secreted from the kidney. Ang I is cleaved to Ang II by angiotensin converting enzyme (ACE) that is mainly distributed in pulmonary circulation. Ang II plays a main role in the RAS by interacting with its specific receptor, Ang II type 1 receptor (AT1R). Ang II-AT1R interaction causes vasoconstriction and aldosterone release from the adrenal gland. This classical view of the RAS has been expanded by recent findings that RAS is activated locally, particularly in the heart 2) , the vessel wall 3) , the kidney 4) and the brain 5) . There are RAS components in these tissues, allowing local synthesis of Ang peptides. Recent reports also identified other receptors 6) and angiotensin-related peptides such as Ang (1-7) 7) . Ang II was also reported to be generated by other enzymes such as chymase 8) . These findings indicate that RAS could be activated locally and regulated by the complicated crosstalk of the RAS components in each organ.
Local effects of an activated RAS in vasculature
The RAS serves as a key player in the pathogenesis of atherosclerosis by simulating a series of coordinated cellular and molecular events observed in the lesions 9) . It is now well established that Ang II has significant pro-inflammatory actions on the vessel wall, leading to progression of atherosclerosis 10) . There are two different types of Ang II receptors, AT1R and AT2R, in mammals. Both AT1R and AT2R have been identified in the vessel wall, although AT1R is believed to mediate most of the atherogenic actions of Ang II 11) . The greatest AT1R density has been found on vascular smooth muscle cells and endothelial cells. In the vascular wall, ACE is readily detectable on endothelial cells and smooth muscle cells 12) . Most of the components of RAS could be detected in vasculature 13) . RAS is activated locally in the atherosclerotic lesions 14) and in the damaged vessels 15) . Thus, these results suggest that not only systemic but also local Ang II-AT1R pathway could contribute to initiation and progression of atherosclerosis.
Effects of RAS on vascular cells
Ang II up-regulates expression of adhesion molecules 16) , chemokines 17) and cytokines 18) . These molecules induce endothelial cell dysfunction 19) , oxidation and uptake of LDL 20) , and proliferation of smooth muscle cells 21) . In advanced atherosclerotic lesions, Ang II stimulates expression of matrix metalloproteinases (MMPs) 22) and plasminogen activator inhibitor-1 23) , leading to destabilization of atherosclerotic plaque and alteration of fibrinolytic balance. Ang II also up-regulates expression of VEGF that promotes adventitial angiogenesis 24) (Fig. 1) . Conversely, previous reports demonstrated that inhibition of the Ang II-AT1R pathway reduces atherosclerosis 25, 26) . It is generally assumed that the beneficial effects obtained by Ang II-AT1R blocking are mediated by reduction of oxidative stress, inhibition of inflammation and improvement of endothelial cell function 27) . We generated apolipoprotein E (ApoE)-/-AT1aR-/-double knockout mice by cross-breeding ApoE-/-AT1aR+/+ mice and ApoE+/+AT1aR-/-mice 28) . Moreover, genetic disruption of AT1R resulted in reduced lipid deposition and increased collagen contents in the atheroma. These results demonstrated that blockade of Ang II-AT1R pathway not only reduces atherosclerotic lesions but also stabilizes the plaque 28) . It should be noted that the production of Ang II could be increased and may act on the AT2R, when AT1R is genetically disrupted or pharmacologically blocked 29) . Previous reports suggested an anti-atherogenic effect of AT2R, although its function and distribution are still under debate 30) . AT2R stimulation interacts with AT1R stimulation at intracellular signaling molecules, such as through activation of phosphatase 31) . In fact, Iwai et al. demonstrated that AT2R stimulation attenuates atherosclerosis through inhibition of oxidative stress and that the anti-atherosclerotic effect of an ARB could be at least partly due to AT2R stimulation by analyzing AT2R/ApoE-double-knockout mice 32) .
Pharmacological inhibition of renin-angiotensin system
AT1R blockers (ARBs) specifically block Ang II binding to AT1R. Eventually, Ang II is directed to stimulate AT2R. On the other hand, ACE inhibitors (ACEIs) suppress angiotensin II production. ACEIs also inhibit break down of bradykinin, leading to increase in nitric oxide production. It has been reported that ARBs or ACEIs exert various favorable effects on endothelial function 25, 26, 33) , cardiac function 34) , cerebral vascular function 35) and renal function 36) other than blood pressure lowering. These findings suggest that blockade of RAS is an effective strategy for organ protection 25, 26, 33) . In fact, many clinical studies demonstrated that AT1R blockers (ARBs) or ACE inhibitors are effective for patients with cardiovascular, cerebrovascular and renal diseases 37) . 
Atherosclerosis is an inflammatory disease
Atherosclerosis occurs in whole arteries and results in various organ damages, including myocardial infarction, cerebral infarction, and peripheral arterial diseases, the main cause of death in Western countries 38) . Atherosclerosis is considered to be one of the chronic inflammatory diseases 10) . Although multifactorial in etiology, continuous recruitment of circulating leukocytes into the vessel wall plays crucial roles in the pathogenesis of atherosclerosis. Inflammatory cells detected in atherosclerotic lesions are derived from bone marrow (Fig. 2) . Recent advances in immunology have identified several molecular pathways that induce and promote inflammatory responses in atherosclerotic lesions.
Roles of reactive oxygen species in atherogenesis
Accumulating evidence indicates that vascular reactive oxygen species (ROS) play a crucial role in atherogenesis. Among many ROS generators, nicotinamide dinucleotide phosphate (NAD(P)H) oxi-dase-dependent pathway is important in vascular system 39) . Barry-Lane et al. demonstrated that NAD(P)H oxidase is important in the pathogenesis of atherosclerosis by analyzing the genetically modified mice that are deficient for both ApoE and p47phox, one subunits of NAD(P)H oxidase 40) . In this study, the double knockout mice showed significant reduction in atherosclerotic lesion compared with that of ApoE-deficient mice. ROS acts not only as a modulator of vascular tonus but also as a second messenger to alter the vascular cell phenotypes. ROS activates mitogen-activated protein kinase 41) , Akt 42) , and JAK (janus kinase)/STAT (signal transducers and activators of transcription) 43) pathways. These signals play a crucial role in cell proliferation, apoptosis and phenotypic modification that are observed in atherosclerotic lesions.
Fig. 2 Atherosclerosis is an inflammatory disease
Ang II has significant pro-inflammatory actions on the vessel wall, leading to progression and destabilization of atherosclerotic lesions 10, 86) . Although multifactorial in etiology, continuous recruitment of circulating leukocytes into the vessel wall plays crucial roles in the pathogenesis of atherosclerosis. Inflammatory cells detected in atherosclerotic lesions are derived from bone marrow.
Association between RAS and ROS has been investigated extensively 3) . Ang II induces production of ROS, one of the most important mediators of the atherogenic actions of RAS 44) . Although Ang II up-regulates expression of cytokines such as interleukin-6 and tumor necrosis factor-α, pharmacological blockade of AT1R with ARBs would not so effective to inhibit cytokine production completely. It was demonstrated that cytokines such as TNF-α, IL-1β and IFN-γ increase mitochondrial-and NADPH oxidase-generated ROS 45) . Thus, the in vivo inhibition of intracellular ROS production by blocking vascular AT1R may play an adjunct rather than a major role to prevent or reduce atherogenesis. The above suggestion could be also compatible with the accumulating findings that AT1R blocker could only have a modest effect on atherosclerosis diseases in patients 46) .
Roles of inflammatory cells in atherogenesis
In initiation and progression of atherosclerotic lesions, RAS is activated locally and stimulates expression of vascular cellular adhesion molecule-1, intracellular adhesion molecule-1 and monocyte chemotactic protein-1 (MCP-1) 16) . These molecules accelerate recruitment of inflammatory cells into the vessel walls. It is generally believed that the vascular endothelium serves as an inflammatory barrier by providing a nonadherent surface to leukocytes. However, upon Ang II stimulation, endothelium turns to promote infiltration of inflammatory cells by expressing adhesion molecules and chemokines. After migrating into the vessel wall, monocytes transform into macrophages and contribute to lipid deposition in the plaque 47) . Monocytes/macrophages se-cret chemokines 48) and MMPs 49) , leading to acceleration of atherosclerotic lesion development. Moreover, recruited leukocytes themselves have NAD(P)H oxidase subunits and serve as a source of ROS 50) . Thus, activated RAS promotes interaction between circulating leukocytes and vascular cells, an important step in the pathogenesis of atherosclerosis 9) . High levels of ACE expression and Ang II have been shown in experimental and human atherosclerotic lesions 51) . In human atherosclerotic lesions, ACE, Ang II, and its receptor are co-localized at the areas of inflammation 3) . Taken together, these results suggest that local effects of an activated RAS in vessel walls promote infiltration of inflammatory cells into the vessel walls, a key feature of atherosclerosis.
Local effects of an activated RAS in bone marrow
Bone marrow is a highly organized organ. All blood cells derive from hematopoietic stem cells through complex steps of division and maturation. Previous reports elucidated the surface receptors, cytokines, and growth factors that potentially regulate hematopoiesis 52) . However, the precise mechanism by which the proliferation and differentiation of hematopoietic stem cells are regulated is not fully understood.
A locally activated RAS has been suggested to contribute to differentiation and proliferation of bone marrow-derived cells 53) . Recently, we proposed a hypothesis that the local RAS in bone marrow plays crucial roles in atherosclerosis 25, 28) . We demonstrated that Ang II-AT1R pathway in bone marrow contributes to atherosclerotic development in the hypercholesterolemic mice.
Randomized clinical trials have proved beneficial effects of ACE inhibitors or ARBs in the treatment of cardiovascular diseases 54) . However, it was reported that ACE inhibitors or ARBs may have suppressive effects on hematological processes. It is reported that ACE inhibitors induced anemia and leukocytopenia 55) . ACE inhibitors and ARBs have been shown to effectively reduce hematocrit values in patient with renal transplantation 56) . Haznedaroglu et al. proposed the existence of a locally activated RAS in bone marrow that contributes to hematological processes 57) . Others also demonstrated the presence of RAS components in bone marrow and circulating blood cells. Rodgers 59, 60) . Similarly, other reports demonstrated that RAS components in bone marrow contribute to hematopoiesis 61) . On the other hand, several papers reported that a local RAS in bone marrow plays a role in the pathological hematopoiesis 62) . Bone marrow stromal cells also express AT1R, whose activation possibly causes secretion of growth factors or cytokines that increase hematopoietic progenitor cells 63) . Thus, it is likely that angiotensin peptides are potential stimulators of proliferation and differentiation of multiple hematopoietic lineages under physiological and pathological conditions.
Ang II stimulates contribution of bone marrow-derived cells to the pathogenesis of atherosclerosis
Recently, we proposed that bone marrow-derived cells significantly contribute to pathogenesis of atherosclerosis 25, 28, [64] [65] [66] [67] [68] [69] [70] [71] . This phenomenon was confirmed not only in animal models of vascular diseases, but also in human samples 72, 73) . Ang II is supposed to promote contribution of bone marrow-derived cells to atherosclerosis by enhancing their mobilization, recruitment, differentiation, and proliferation 25, 28) . To confirm this notion, we performed bone marrow transplantation from GFP (Green Fluorescent Proteins)+/+ApoE-/-mice to GFP-/-ApoE-/-mice. Administration of Ang II to these bone marrow chimeric mice promoted atherosclerosis lesion formation, which was associated with increased infiltration of bone marrow-derived GFP-positive cells to the lesion 25, 28) (Fig. 3A) . We also observed that Ang II infusion increased the number of smooth muscle progenitor cells, which are peripheral blood cells that turn to α-smooth muscle actin-positive cells after culture in the presence of PDGF-BB 70) (Fig. 3B) . These smooth muscle-like cells expressed abundant matrix metalloproteinase-9 (MMP-9), which substantially contribute to destabilization of atherosclerotic plaques. RAS and inflammation 
RAS and endothelial progenitor cells
It is a generally accepted view that atherosclerotic lesions are initiated by endothelial cell damage, followed by monocyte/macrophage adhesion and invasion as well as smooth muscle cell migration and proliferation 74, 75) . Although there are a number of cellular and molecular differences, restenosis after angioplasty shares an important pathophysiological process with atherosclerosis, where injuries to the endothelium are followed by impaired re-endothelialization 76, 77) . It has been believed that re-endothelialization is caused only by migration and proliferation of adjacent endothelial cells in the vessel wall 78) . However, accumulating evidence indicates that bone marrow derived endothelial progenitor cells (EPCs) also participate in this process 79) . EPC-dependent neovascularization has been implicated in collateral development in occlusive vascular diseases 80) . Bone marrow cells including stem cells express AT1R. Thus, it is possible that a local RAS in bone marrow has a role in EPC biology leading to neovascularization. Actually, it was demonstrated that activation of RAS stimulates EPC proliferation and neovascularization 81) . These studies suggest that ROS may be involved in the balance between self-renewal and differentiation of progenitors and that anti-oxidant may play a role in preservation of stemness of progenitors 82) . Murohara and his colleagues showed that the Ang II-AT1R pathway plays an important role in ischemia-induced angiogenesis by supporting inflammatory cell infiltration and angiogenic cytokine expression 83) . On the other hand, it was reported that blockade of RAS increase the number of EPC and neovascularization in animals models of metabolic diseases 84) . These studies suggested that Ang II accelerates the onset of EPC senescence by a gp91phox-mediated increase of oxidative stress leading to impairment of EPC proliferation. Under pathological conditions, RAS may be over-activated and the excess production of Ang II might accelerate EPC senescence, resulting in the impairment of EPC function. Future study is required to confirm that RAS is essential for EPC proliferation and neovascularization but excessive activation of RAS may turn to enhance senescence and dysfunction of EPCs 71) .
Closing remarks
Our findings demonstrate that RAS not only in vessel wall but also in bone marrow-derived cells plays a role in the pathogenesis of atherosclerosis, at least in part, by accelerating infiltration of bone marrow-derived inflammatory cells in the vessel wall 28, 67, 85) . Therefore, blockade of AT1 receptor not only in vascular cells but also in bone marrow could be an important strategy to prevent progression and destabilization of atherosclerotic plaques. Elucidation of molecular mechanism of chronic inflammation should lead to development of effective strategies against lifestyle-related diseases.
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